Los Angeles Capital Management
KDNY

Los Angeles Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Los Angeles Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,477
Closed -$40K – 1549
2020
Q2 		$40K Sell
3,477
-7,393
-68% -$102K ﹤0.01% 1441
2020
Q1 		$149K Buy
+10,870
New +$129K ﹤0.01% 1238

Other funds holding KDNY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Los Angeles Capital Management's KDNY Position: Q3 2020 in Review

Los Angeles Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2020, closing a stake of 3,477 shares — an estimated $40K sold.

Los Angeles Capital Management first reported a position in KDNY in Q1 2020 and held it in 2 quarters. The position peaked at $149K in Q1 2020. 70 funds tracked by Wall St. Rank hold KDNY as of Q3 2020.

  • Los Angeles Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Los Angeles Capital Management sold 3,477 Chinook Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $40K.
  • Los Angeles Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2020 and held it in 2 quarters.
  • Los Angeles Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $149K in Q1 2020.
  • 70 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Los Angeles Capital Management's 13F filing for Q3 2020, filed 2 Nov 2020.